Recursion Pharmaceuticals Inc
NASDAQ:RXRX
Intrinsic Value
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel med... [ Read More ]
The intrinsic value of one
RXRX
stock under the Base Case scenario is
3.41
USD.
Compared to the current market price of 7.61 USD,
Recursion Pharmaceuticals Inc
is
Overvalued by 55%.
RXRX's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
RXRX or that its price is influenced by factors unrelated to fundamentals.
Recursion Pharmaceuticals Inc's market capitalization is 1.8B USD.
RXRX stock price is 7.61 USD.
RXRX stock (3.41 USD) is 55% less than its price (7.61 USD).
RXRX. Open DCF Valuation
RXRX stock (3.41 USD) is 55% less than its price (7.61 USD). Open Relative Valuation
RXRX has upside potential of 74% compared to the average analyst price target.
Open Wall St Estimates
RXRX's Revenue has grown by 12% over the past 12 months.
RXRX has negative Operating Income for the last twelve months.
RXRX has negative Net Income for the last twelve months.
RXRX's ROE (Return on Equity) for the past 12 months is negative and is equal to -69%.
RXRX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -170%.
RXRX's Revenue is forecast to grow at a rate of 51% per year over the next 3 years.
RXRX's Altman Z-Score is very high and is equal to 3.42.
RXRX has positive Gross Profit for the last twelve months.
RXRX has negative Free Cash Flow for the last twelve months.
RXRX's long-term assets (654m USD) exceed its long-term liabilties (190m USD).
RXRX's D/E (Debt to Equity) is very low and is equal to 0.
RXRX has negative three-year average ROE (Return on Equity): -51%. The company is not efficient at transforming stockholders' equity into net income.
RXRX has negative three-year average ROIC (Return on Invested Capital): -185%. The company is not efficient at using invested capital to generate operating income.
RXRX's short-term assets (438m USD) exceed its short-term liabilties (93m USD).
RXRX has negative Net Debt. This means that the company has more cash and short-term investments (392m USD) than debt (1m USD).
RXRX doesn't generate enough operating income (-349m USD) to safely cover interest payments on its debt (96k USD).
Valuation Backtest
Recursion Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
RXRX
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Recursion Pharmaceuticals Inc
Balance Sheet Decomposition
Recursion Pharmaceuticals Inc
| Current Assets | 438.1m |
| Cash & Short-Term Investments | 391.6m |
| Receivables | 3.1m |
| Other Current Assets | 43.5m |
| Non-Current Assets | 215.6m |
| PP&E | 120.2m |
| Intangibles | 88.5m |
| Other Non-Current Assets | 6.9m |
| Current Liabilities | 93.2m |
| Accounts Payable | 4m |
| Accrued Liabilities | 52.8m |
| Other Current Liabilities | 36.5m |
| Non-Current Liabilities | 97.1m |
| Long-Term Debt | 1.1m |
| Other Non-Current Liabilities | 96m |
Earnings Waterfall
Recursion Pharmaceuticals Inc
|
Revenue
|
44.6m
USD
|
|
Cost of Revenue
|
-42.6m
USD
|
|
Gross Profit
|
2m
USD
|
|
Operating Expenses
|
-350.8m
USD
|
|
Operating Income
|
-348.9m
USD
|
|
Other Expenses
|
20.8m
USD
|
|
Net Income
|
-328.1m
USD
|
Free Cash Flow Analysis
Recursion Pharmaceuticals Inc
RXRX Profitability Score
Profitability Due Diligence
Recursion Pharmaceuticals Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Recursion Pharmaceuticals Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
RXRX Solvency Score
Solvency Due Diligence
Recursion Pharmaceuticals Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Score
Recursion Pharmaceuticals Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RXRX Price Targets Summary
Recursion Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
RXRX
is 13.26 USD
with a low forecast of 10.1 USD and a high forecast of 17.85 USD.
Ownership
RXRX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
RXRX Price
Recursion Pharmaceuticals Inc
| Average Annual Return | -50.27% |
| Standard Deviation of Annual Returns | 11.12% |
| Max Drawdown | -89% |
| Market Capitalization | 1.8B USD |
| Shares Outstanding | 234 650 000 |
| Percentage of Shares Shorted | 25.44% |
RXRX News
Last Important Events
Recursion Pharmaceuticals Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Recursion Pharmaceuticals Inc
Company Profile
Recursion Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. The company is headquartered in Salt Lake City, Utah. The company went IPO on 2021-04-16. The Company’s platform includes the Recursion Operating System, which combines an advanced infrastructure layer to generate proprietary biological and chemical datasets, and the Recursion Map, a suite of custom software, algorithms, and machine learning tools. The Company’s programs include REC-994, REC-2282, REC-4881, and REC-3599. REC-994 is an orally bioavailable, superoxide, scavenger small molecule being developed for the treatment of CCM. REC-2282 is developed for the treatment of neurofibromatosis type 2. REC-4881 is developed for the treatment of familial adenomatous polyposis. REC-3599 is developed for the treatment of GM2 gangliosidosis.
Contact
IPO
Employees
Officers
The intrinsic value of one
RXRX
stock under the Base Case scenario is
3.41
USD.
Compared to the current market price of 7.61 USD,
Recursion Pharmaceuticals Inc
is
Overvalued by 55%.
You don't have any saved screeners yet
